Reports Q2 revenue $546.6M, consensus $476.84M. “We delivered outstanding results in the second quarter, with record Signatera (NTRA) growth and continued strength across our women’s health and organ health product lines,” said Steve Chapman, chief executive officer of Natera. “We’re raising our outlook for the year and advancing a robust pipeline of data and innovation to help even more patients in the future.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA: